Are there antibody-drug conjugates approved for Appendiceal Cancer

Antibody-Drug Conjugates (ADCs) for Appendiceal Cancer

Based on current NCCN Guidelines for Appendiceal Neoplasms and Cancers, there is one FDA-approved antibody-drug conjugate specifically mentioned for appendiceal cancer treatment:

Fam-trastuzumab deruxtecan-nxki (T-DXd)

What it is: This is an antibody-drug conjugate that targets HER2-positive cancers. Think of it as a "guided missile"—an antibody (the delivery system) carries a chemotherapy drug directly to cancer cells that have HER2 protein on their surface.

When it's used: According to NCCN Guidelines, fam-trastuzumab deruxtecan is recommended for:

• HER2-positive appendiceal adenocarcinomas (specifically IHC 3+ status)
• Typically used in the palliative (advanced disease) setting
• Given as an IV infusion every 21 days at a dose of 5.4 mg/kg

Why this matters: HER2-positive tumors represent a specific subset of appendiceal cancers where the cancer cells produce extra copies of the HER2 protein. This makes them responsive to HER2-targeted therapies.

Important Context

The NCCN Guidelines emphasize that biomarker testing is recommended for all patients with appendiceal cancer to identify actionable mutations—including HER2 status. This testing helps determine which targeted therapies (like ADCs) might be appropriate for your specific cancer.

Questions to ask your oncology team:

1. Has my tumor been tested for HER2 status?
2. If HER2-positive, am I a candidate for fam-trastuzumab deruxtecan?
3. What other biomarkers have been tested on my tumor (BRAF, KRAS, MSI/dMMR status)?
4. Are there clinical trials available for appendiceal cancer with newer ADCs?

According to the NCCN Guidelines for Appendiceal Neoplasms and Cancers (Version 1.2026), treatment decisions should be made through multidisciplinary team evaluation based on your complete clinical picture, including disease stage, histologic type, and molecular characteristics.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.